108
angiotensin I converting enzyme inhibitors.
Farmacia 63:492–503
12. Dharani S, Subedari H, Panakanti PK, Yamsani
MR (2013) Preparation and evaluation of
novel expandable drug delivery system with
captopril current drug therapy. Curr Drug
Ther 8:206–214
13. Hua Z, Shaofeng L, Gareth RW et al (2012) A
systematic study of captopril-loaded polyester
fiber mats prepared by electrospinning. Int J
Pharm 439:100–108
14. Wei A, Wang J, Wang X et al (2012)
Morphology and surface properties of poly
(L-lactic acid)/captopril composite nanofiber membranes. J Engineered Fibers Fabrics
7(1):129–135
15. Suguna LM, Joseph SW, Mandal AB et al
(2012) Intestine-specific, oral delivery of
captopril montmorillonite: formulation
and release kinetics. Nanoscale Res Lett
7(15):1–8
16. Khamanga SM, Walker RB (2012) In vitro
dissolution kinetics of captopril from microspheres manufactured by solvent evaporation.
Dissolution Technologies, February 42–51
17. Propovici RF, Alexa IF, Novac O, Vinceanu N
et al (2011) Pharmacokinetics study on mesoporous silica-captopril controlled release systems.
Dig J Nanomater Biostruct 6(4):1619–1630
18. Popovici RF, Seftel EM, Mihai GD (2011)
Controlled drug delivery system based on
ordered mesoporous silica matrices of captopril
as angiotensin-converting enzyme inhibitor
drug. J Pharm Sci 100(2):704–714
19. Grdadolnik SG, Pristovšek P, Mierke DF
(1997) Vancomycin: interactions with a cell
model membrane. Biopolymers 42:627–632
20. Casy AF, Dewar GH (1994) Captopril and
its probable contaminants: NMR and MS features of analytical value. J Pharm Biomed Anal
12(7):855–861
21. Griesinger C, Ernst RR (1987) Frequency
offset effects and their elimination in NMR
rotating-frame cross-relaxation spectroscopy. J
Magn Reson 75:261–271
22. Kyrikou I, Grdadolnik SG, Tatari M, Poulos
C, Mavromoustakos T (2003) Structural elucidation and conformational properties of the
toxin paralysin b-Ala/Tyr. J Pharm Biomed
Anal 31:713–721
Evangelia Soumelidou et al.
angiotensin I converting enzyme inhibitors.
Farmacia 63:492–503
12. Dharani S, Subedari H, Panakanti PK, Yamsani
MR (2013) Preparation and evaluation of
novel expandable drug delivery system with
captopril current drug therapy. Curr Drug
Ther 8:206–214
13. Hua Z, Shaofeng L, Gareth RW et al (2012) A
systematic study of captopril-loaded polyester
fiber mats prepared by electrospinning. Int J
Pharm 439:100–108
14. Wei A, Wang J, Wang X et al (2012)
Morphology and surface properties of poly
(L-lactic acid)/captopril composite nanofiber membranes. J Engineered Fibers Fabrics
7(1):129–135
15. Suguna LM, Joseph SW, Mandal AB et al
(2012) Intestine-specific, oral delivery of
captopril montmorillonite: formulation
and release kinetics. Nanoscale Res Lett
7(15):1–8
16. Khamanga SM, Walker RB (2012) In vitro
dissolution kinetics of captopril from microspheres manufactured by solvent evaporation.
Dissolution Technologies, February 42–51
17. Propovici RF, Alexa IF, Novac O, Vinceanu N
et al (2011) Pharmacokinetics study on mesoporous silica-captopril controlled release systems.
Dig J Nanomater Biostruct 6(4):1619–1630
18. Popovici RF, Seftel EM, Mihai GD (2011)
Controlled drug delivery system based on
ordered mesoporous silica matrices of captopril
as angiotensin-converting enzyme inhibitor
drug. J Pharm Sci 100(2):704–714
19. Grdadolnik SG, Pristovšek P, Mierke DF
(1997) Vancomycin: interactions with a cell
model membrane. Biopolymers 42:627–632
20. Casy AF, Dewar GH (1994) Captopril and
its probable contaminants: NMR and MS features of analytical value. J Pharm Biomed Anal
12(7):855–861
21. Griesinger C, Ernst RR (1987) Frequency
offset effects and their elimination in NMR
rotating-frame cross-relaxation spectroscopy. J
Magn Reson 75:261–271
22. Kyrikou I, Grdadolnik SG, Tatari M, Poulos
C, Mavromoustakos T (2003) Structural elucidation and conformational properties of the
toxin paralysin b-Ala/Tyr. J Pharm Biomed
Anal 31:713–721
Evangelia Soumelidou et al.